Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Dr Reddy's gets 2 observations from USFDA for formulation plant

Feb 28, 2020, 17:11 IST

PTI

New Delhi, Feb 28 () Dr Reddy's Laboratories on Friday said the US health regulator has issued a Form 483 with two observations after inspecting one of its formulation plants in Hyderabad.

In a regulatory filing, the drug major said the US Food and Drug Administration (USFDA) completed audit of its formulations manufacturing plant - 3 at Bachupally, Hyderabad on Friday.

"We have been issued a Form 483 with two observations. We will address them comprehensively within the stipulated timeline," it added.

As per the USFDA, Form 483 is issued to firm management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.

Dr Reddy's shares on Friday ended 4.66 per cent up at Rs 2,925.80 apiece on the BSE. MSS MSS ANUANU

(This story has not been edited by www.businessinsider.in and is auto–generated from a syndicated feed we subscribe to.)